TheraVida, Inc.
http://www.theravida.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From TheraVida, Inc.
Deal Watch: Allogene Gets Pfizer's Off-The-Shelf CAR-T Program, $300m Series A Backing
Celgene reworks its collaboration with Abide, dropping its buyout option. Roivant gains Chinese rights to anti-infective lemafulin and adds a fifth candidate to Dermavant's pipeline, while pSivida acquires Icon and FDA-approved Dexycu for cataract surgery inflammation.
Deals Shaping The Medical Industry, June 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
Livin' TheraVida loca: Tolenix and follow-on licensed to Korea's SK
The news in a nutshell
TheraVida to conduct more studies of Tolenix after reporting positive Phase II data
TheraVida said it intends to conduct additional international clinical trials of its lead product candidate, Tolenix (THVD-201), for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI) having reported positive Phase II data for the drug.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice